Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Caux

Showing results (101-110 of 142) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|July 22, 2014
Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cellsFlorence Deauvieau, Vincent Ollion, Anne-Claire Doffin, et al.
Oncoimmunology|June 28, 2024
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patientsStéphane Dalle, Estelle Verronese, Axelle N'Kodia, et al.
Cancer Research|May 16, 2015
Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease SubtypesCristina Ghirelli, Fabien Reyal, Marine Jeanmougin, et al.
Nature Communications|June 4, 2020
Durable and controlled depletion of neutrophils in miceGael Boivin, Julien Faget, Pierre-Benoit Ancey, et al.
Journal of Innate Immunity|June 23, 2025
TLR9 Downregulation in Breast Cancer: Its Role in Tumor Immunity, Inflammatory Response, and Cellular SenescenceEmily Sible, Gregory Weitsman, Salome Amouyal, et al.
Stem Cell Reports|January 21, 2015
Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell responseMarion Chapellier, Elodie Bachelard-Cascales, Xenia Schmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2012
CD4 lymphopenia to identify end-of-life metastatic cancer patientsJulien Péron, Claire Cropet, Olivier Tredan, et al.
Therapeutic Advances in Medical Oncology|August 11, 2025
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacyOlivia Le Saux, Renaud Sabatier, Isabelle Treilleux, et al.
Journal for Immunotherapy of Cancer|November 8, 2023
MDR1-EXPRESSING CD4<sup>+</sup> T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSEAnthony Di Roio, Margaux Hubert, Laurie Besson, et al.
Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.
Pageof 15

Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|July 22, 2014
Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cellsFlorence Deauvieau, Vincent Ollion, Anne-Claire Doffin, et al.
Oncoimmunology|June 28, 2024
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patientsStéphane Dalle, Estelle Verronese, Axelle N'Kodia, et al.
Cancer Research|May 16, 2015
Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease SubtypesCristina Ghirelli, Fabien Reyal, Marine Jeanmougin, et al.
Nature Communications|June 4, 2020
Durable and controlled depletion of neutrophils in miceGael Boivin, Julien Faget, Pierre-Benoit Ancey, et al.
Journal of Innate Immunity|June 23, 2025
TLR9 Downregulation in Breast Cancer: Its Role in Tumor Immunity, Inflammatory Response, and Cellular SenescenceEmily Sible, Gregory Weitsman, Salome Amouyal, et al.
Stem Cell Reports|January 21, 2015
Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell responseMarion Chapellier, Elodie Bachelard-Cascales, Xenia Schmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2012
CD4 lymphopenia to identify end-of-life metastatic cancer patientsJulien Péron, Claire Cropet, Olivier Tredan, et al.
Therapeutic Advances in Medical Oncology|August 11, 2025
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacyOlivia Le Saux, Renaud Sabatier, Isabelle Treilleux, et al.
Journal for Immunotherapy of Cancer|November 8, 2023
MDR1-EXPRESSING CD4<sup>+</sup> T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSEAnthony Di Roio, Margaux Hubert, Laurie Besson, et al.
Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.
Pageof 15